Claire Xu

Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer

Yujun Hao, Yardena Samuels, Qingling Li et al. · Nature Communications · 2016 · 300 citations · Full text

Medicine, Cancer Biology, Oncology +17

Lemzoparlimab, a Differentiated Anti-CD47 Antibody in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin's Lymphoma: Initial Clinical Results

Amitkumar Mehta, Wael A. Harb, Claire Xu et al. · Blood · 2021 · 32 citations

Pharmacy, Immunology, Pharmacotherapy +16

A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors

Geoffrey Y. Ku, Lin Shen, Farshid Dayyani et al. · Clinical Cancer Research · 2025 · 15 citations · Full text

Medicine, Oncology, Pharmacology +17

Preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer.

Francisco Robert, Ecaterina E. Dumbrava, Yan Xing et al. · Journal of Clinical Oncology · 2021 · 13 citations

Medicine, Oncology, Pharmacology +17